AlloVir General and Administrative Expenses 2011-2025 | ALVR

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses AlloVir

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
42.9 M	48.3 M	52.3 M	49.1 M	21.6 M	10.6 M	3.03 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
52.3 M	3.03 M	32.6 M

Quarterly General and Administrative Expenses AlloVir

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
2.48 M	2.72 M	3.65 M	-	1.25 M	417 K	393 K	-	12.8 M	12.5 M	12.5 M	-	12.9 M	13.2 M	14.1 M	-	12.4 M	12 M	10.5 M	-	6.72 M	3.27 M	3 M	-	2.82 M	3.19 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
14.1 M	393 K	7.15 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Amphastar Pharmaceuticals AMPH	56.7 M	$ 25.27	-2.43 %	$ 1.22 B	USA
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	22.5 M	$ 4.75	1.61 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	22.2 M	$ 3.26	-3.12 %	$ 252 M	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	73.5 M	-	-15.15 %	$ 60.3 M	Britain
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Aeglea BioTherapeutics AGLE	45.8 M	-	-	$ 1.01 B	USA
Kamada Ltd. KMDA	12.6 M	$ 7.03	0.14 %	$ 260 M	Israel
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Ascendis Pharma A/S ASND	160 M	$ 220.27	4.81 %	$ 5 B	Danmark
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Enlivex Therapeutics Ltd. ENLV	232 K	$ 0.91	-5.01 %	$ 18.7 M	Israel
Can-Fite BioPharma Ltd. CANF	3.05 M	$ 0.28	-2.28 %	$ 609 M	Israel
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.3	-3.51 %	$ 7.94 B	Australia
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
AstraZeneca PLC AZN	15.2 B	$ 89.78	-0.57 %	$ 96.9 B	Britain
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Anika Therapeutics ANIK	95.8 M	$ 9.57	0.84 %	$ 140 M	USA
Brickell Biotech BBI	11.2 M	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	1.83 B	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	5.72 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	95.1 M	-	-7.31 %	$ 87 M	USA
Benitec Biopharma BNTC	6.97 M	$ 12.05	-7.06 %	$ 496 M	USA
Aytu BioScience AYTU	17.4 M	$ 2.34	2.59 %	$ 14.7 M	USA
Nymox Pharmaceutical Corporation NYMX	5.85 M	-	-19.68 %	$ 18.4 M	Canada
Arena Pharmaceuticals ARNA	126 M	-	-6.81 %	$ 3.04 B	USA
Aptorum Group Limited APM	5.41 M	$ 1.29	-3.01 %	$ 7.03 M	China
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Baudax Bio BXRX	24.1 M	-	0.59 %	$ 63 K	USA
Avenue Therapeutics ATXI	4.64 M	-	-52.27 %	$ 4.45 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Catalyst Biosciences CBIO	14.7 M	$ 14.01	-8.49 %	$ 922 M	USA
ChromaDex Corporation CDXC	18.4 M	-	-0.88 %	$ 598 M	USA
Axon Enterprise AXON	741 M	$ 566.18	-2.56 %	$ 42.9 B	USA
Cerus Corporation CERS	75.9 M	$ 2.16	0.47 %	$ 399 M	USA
Checkpoint Therapeutics CKPT	20.1 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	12.1 M	-	-16.75 %	$ 25.8 M	USA
Clovis Oncology CLVS	128 M	-	-7.23 %	$ 13 M	USA
Biogen BIIB	2.4 B	$ 174.42	1.11 %	$ 25.4 B	USA
BioVie BIVI	8.57 M	$ 1.42	-5.96 %	$ 2.1 M	USA
Celldex Therapeutics CLDX	38.5 M	$ 27.36	-2.09 %	$ 1.76 M	USA
Cortexyme CRTX	17.7 M	-	-1.05 %	$ 67.1 M	USA
Cellectar Biosciences CLRB	11.7 M	$ 3.63	-3.97 %	$ 44.4 M	USA
Deciphera Pharmaceuticals DCPH	136 M	-	-	$ 2.18 B	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	714 M	$ 11.54	0.87 %	$ 746 M	USA